“There is data that the vaccine is effective even for the elderly”
viewer
AstraZeneca said, “The production of a new coronavirus infection (Corona 19) vaccine in Europe is two months behind the original plan.”
On the 27th (local time) Pascal Sorio AstraZeneca, CEO of AstraZeneca, said in an interview with the German Daily Belt, “the vaccine production is carried out in two stages. First, the vaccine itself is produced and then put in ampoules.” “In the Netherlands, Belgium, and later ampoules in Germany and Italy, this process is fine.” “The problem is that productivity is low in cultivating raw materials.” “We put the virus in a large tank holding up to 2,000 liters to cultivate raw materials for the production of Corona 19 vaccine. The lowest situation.”
CEO Sorio pointed out that the EU’s vaccine orders were three months behind the UK, denying allegations that AstraZeneca deliberately delayed supply to the EU and exported to other regions. “There was an initial problem with the vaccine supply to the UK as well, but a vaccine supply contract with the UK was signed three months before the EU,” he said. “This means that it took three more months to correct the breakdown and the like. “It is an inevitable reality that Europe has a facility with the lowest raw material productivity.
Regarding the delay in the supply of vaccines to the EU, he said, “We said we would do our best, but we have no contractual supply obligations. We like our ambitious goals, but we didn’t endorse them.” .
He said, “We produce 17 million batches per month.” Germany will be supplied with 3 million servings per month, he predicts.
Meanwhile, he denied that AstraZeneca’s COVID-19 vaccine is a completely wrong number with respect to German media reports that only 8% of the elderly people aged 65 or older are effective. At the same time, when asked how effective it is for the elderly, “Oxford University did not test for the elderly during the first clinical trial due to ethical issues. There are detailed data.”
“What’s crucial is that our vaccine prevents severe COVID-19 and eliminates the need for hospital treatment,” he said. “I understand that some countries may choose to only vaccinate young people with our vaccine. However, the 50-70-year-old is an important age group for us to protect, and the UK has decided to vaccinate the elderly as well.”
“We are not supplying vaccines for profit,” said Sorio. “We have agreed to do vaccine development with Oxford University without profit.”
/ Reporter Kwak Yoon-ah [email protected]
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >